Biochemical markers of individual response to growth hormone replacement in adults

Hormone Research

Volumn 55, Issue SUPPL. 2, 2001, Pages 49-54

  Monson, John P ^a  

^a ST BARTHOLOMEW S HOSPITAL   (United Kingdom)

Author keywords

Adult growth hormone deficiency; Biochemical markers of growth hormone; Bone remodelling; Growth hormone replacement; Insulin like growth factor binding protein 3; Insulin like growth factor I

Indexed keywords

ACID PROTEIN; ALKALINE PHOSPHATASE; BIOCHEMICAL MARKER; COLLAGEN TYPE 1; DEOXYPYRIDINOLINE; ESTROGEN; GROWTH HORMONE; INSULIN; LEPTIN; OSTEOCALCIN; PROCOLLAGEN; PYRIDINOLINE; SOMATOMEDIN BINDING PROTEIN 3; SOMATOMEDIN C;

ADULT; BODY COMPOSITION; BODY FAT; BONE REMODELING; CLINICAL PRACTICE; CONFERENCE PAPER; CORRELATION ANALYSIS; DISEASE PREDISPOSITION; DOSE CALCULATION; DOSE RESPONSE; DRUG EFFICACY; DRUG OVERDOSE; DRUG RESPONSE; DRUG SAFETY; ESTROGEN THERAPY; GROWTH HORMONE DEFICIENCY; HEALTH STATUS; HORMONE ACTION; HORMONE RESPONSE; HORMONE SENSITIVITY; HORMONE SUBSTITUTION; HUMAN; INDIVIDUALITY; MEASUREMENT; MEDICAL ASSESSMENT; PATIENT MONITORING; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; SEX DIFFERENCE; SYMPTOM; TISSUE DISTRIBUTION; TREATMENT OUTCOME;

BIOLOGICAL MARKERS; GROWTH HORMONE; HORMONE REPLACEMENT THERAPY; HUMANS; OUTCOME ASSESSMENT (HEALTH CARE);

EID: 0035742620     PISSN: 03010163     EISSN: None     Source Type: Journal    
DOI: 10.1159/000063475     Document Type: Conference Paper

References (25)

1. Individualised dose titration of GH during GH replacement in hypopituitary adults
2. Optimising growth hormone replacement therapy by dose titration in hypopituitary adults
3. Dose titration and patient selection increases the efficacy of GH replacement in severely GH-deficient adults
4. Monitoring of serum GH replacement therapy in adults based on measurement of serum markers
5. Growth hormone deficiency in adulthood and the effects of growth hormone replacement: A review
6. An audit of outcome of treatment of acromegaly
7. GH replacement in 1034 GH-deficient hypopituitary adults: Demographic and clinical characteristics, dosing and safety
8. Serum levels of insulin-like growth factor I in 152 patients with growth hormone deficiency, aged 19-82 years, in relation to those in healthy subjects
9. Diagnosis of growth hormone deficiency in adults
10. Acid-labile subunit of human insulin-like growth factor-binding complex: Measurement, molecular and clinical evaluation
11. Effects of growth hormone (GH) on plasma bone Gla protein in GH-deficient adults
12. Growth hormone (GH)-deficient men are more responsive to GH replacement therapy than women
13. Growth hormone dose regimens in adult GH deficiency: Effects on biochemical growth markers and metabolic parameters
14. The effects of two doses of replacement GH on the biochemical, body composition and psychological profiles of GH-deficient adults
15. Gender difference in insulin-like growth factor I response to growth hormone (GH) treatment in GH-deficient adults: Role of sex hormone replacement
16. Diurnal variation in serum insulin-like growth factor-I and IGFBP-3 concentrations during daily subcutaneous injections of rhGH in GH-deficient adults
17. Route of estrogen administration helps to determine growth hormone replacement dose in GH-deficient adults
18. A switch from oral (2 mg/day) to transdermal (50 μg/day) 17β-estradiol therapy increases serum insulin-like growth factor I levels in recombinant human growth hormone (GH)-substituted women with GH deficiency
19. The influence of gender on the short- and long-term effects of growth hormone replacement on bone metabolism and bone mineral density in hypopituitary adults: A 5-year study
20. Gender differences in the effects of long-term growth hormone (GH) treatment on bone in adults with GH deficiency
21. Serum leptin response to the acute and chronic administration of growth hormone (GH) to elderly subjects with GH deficiency
22. Administration of recombinant human GH on alternate days is sufficient to increase whole body protein synthesis and lipolysis in GH-deficient adults
23. A dose-response study of GH replacement on whole body protein and lipid kinetics in GH-deficient adults
24. Pre-treatment IGF-I level is the major determinant of GH dosage in adult GH deficiency
25. Serum IGF-I, IGFBP-1 and -3 and the acid-labile subunit as serum markers of body composition during GH therapy in adults with GH deficiency